TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01620476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
Study: NCT03018431

Intervention type: OTHER
Intervention: CT Scan
Description: patients undergoing chest CT scan at admission and repeated lung ultrasonography
Study: NCT02245737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01191723

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Capsule
Description: Placebo for Moxifloxacin administered in Treatment B and Treatment C

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Capsule
Description: Placebo for Moxifloxacin administered in Treatment B and Treatment C

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Capsule
Description: Placebo for Moxifloxacin administered in Treatment B and Treatment C

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Capsule
Description: Placebo for Moxifloxacin administered in Treatment B and Treatment C

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Capsule
Description: Placebo for Moxifloxacin administered in Treatment B and Treatment C
Study: NCT03345251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrotubation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hydrotubation
Study: NCT05369663

Intervention type: DEVICE
Intervention: mask use
Description: face mask use

Intervention type: DEVICE
Intervention: mask use
Description: face mask use

Intervention type: DEVICE
Intervention: mask use
Description: face mask use

Intervention type: DEVICE
Intervention: mask use
Description: face mask use

Intervention type: DEVICE
Intervention: mask use
Description: face mask use
Study: NCT01259817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGASYS
Description: Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81 or 100 mg daily.
Study: NCT03320668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Description: A nurse/physiotherapist supported by an instructor-trained professional will give Otago Exercise Program (OEP) education to 10-people groups in 5 sessions (1st, 2nd, 4th and 8th week and one reinforcement session after 6 months). Telephone calls to participants will be made during non-training months (following a predefined telephonic interview protocol) to follow up. The OEP reduces the number of falls and fall-related injuries, improving balance and strength, confidence in performing everyday activities without falling. Whilst it has been shown to be effective in 4 controlled trials in New Zealand, it has not been tested in a primary care setting in Spain for feasibility, impact, acceptability and cost-effectiveness.
Study: NCT01676987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed combination of budesonide and formoterol
Description: Delivered dry powder inhaler for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Delivered dry powder inhaler for 12 weeks.
Study: NCT01051674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber vs. low-carbohydrate diets
Description: High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber vs. low-carbohydrate diets
Description: High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
Study: NCT03264274

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Description: Antiangiogenic

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dynamic Contrast Enhanced Ultrasound
Description: DCE-US (a technique using differential liver blood flow assessments using microbubble) will be performed at baseline, Week 2 and 8 of treatment.
Study: NCT01742273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K1
Description: Vitamin K1 to slow vascular calcification
Study: NCT04390126

Intervention type: OTHER
Intervention: life questionnaires
Description: Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)

Intervention type: OTHER
Intervention: life questionnaires
Description: Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)

Intervention type: OTHER
Intervention: life questionnaires
Description: Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)

Intervention type: OTHER
Intervention: life questionnaires
Description: Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)

Intervention type: OTHER
Intervention: life questionnaires
Description: Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)

Intervention type: OTHER
Intervention: life questionnaires
Description: Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)

Intervention type: OTHER
Intervention: life questionnaires
Description: Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)

Intervention type: OTHER
Intervention: life questionnaires
Description: Telephone survey during the confinement period (common questionnaire and a questionnaire specific to the patient's pathology)

Intervention type: OTHER
Intervention: questionnaire
Description: 1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease

Intervention type: OTHER
Intervention: questionnaire
Description: 1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease

Intervention type: OTHER
Intervention: questionnaire
Description: 1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease

Intervention type: OTHER
Intervention: questionnaire
Description: 1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease

Intervention type: OTHER
Intervention: questionnaire
Description: 1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease

Intervention type: OTHER
Intervention: questionnaire
Description: 1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease

Intervention type: OTHER
Intervention: questionnaire
Description: 1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease

Intervention type: OTHER
Intervention: questionnaire
Description: 1-year telephone diary to identify complications resulting in hospitalization related to the patient's chronic disease
Study: NCT01224119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplex
Description: 225 micrograms of B2A per cc of ceramic granules

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft bone
Description: Bone is collected through a separate incision at the iliac crest or tibia.
Study: NCT02742961

Intervention type: OTHER
Intervention: Peripheral nerve block
Description: A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
Study: NCT01475591

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Web-based multimodal rehabilitation based on cognitive based principles
Description: The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
Study: NCT04268082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual biofeedback with the use of sensorized insoles
Description: Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol. The experimental group was re-educated to the correct gait dynamics by wearing the sensorized insoles and by using a specific software's graphical interface as a visual biofeedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation based on physiotherapist's verbal instructions
Description: Between the 4th and the 10th day post surgery, both groups performed the same rehabilitation protocol.The Control group did not wear the insoles, but it carried out the rehabilitation programme under the physiotherapist supervision and with his verbal feedbacks.
Study: NCT04281615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Generic Message
Description: Exposed to four sets of promotional materials hypothesized to increase perceptions of self-efficacy to meet Guidelines.
Study: NCT03535974

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preparation with Spirulina
Description: Preparation with Spirulina to ameliorate the size of benign thyroid nodules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration for 6 weeks bid
Study: NCT00844376

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin suspension
Description: A single dose of 80 mg Atorvastatin suspension

Intervention type: DRUG
Group type: OTHER
Intervention: Lipitor
Description: A single dose of 80 mg Lipitor tablet
Study: NCT00611689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib and PTK/ZK222584
Description: Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in \< 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
Study: NCT04186767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Carb Ketogenic Diet
Description: Patients will be submitted to very low-calorie ketogenic dietary intervention (VLCK) according to the recommendations of the Pronokal® Method program including lifestyle and physical activity guidelines. The ketogenic stage (phase 1-3) consists of a VLCD diet (600-800 kcal / d), with low carbohydrate intake and lipids. The amount of high biological value proteins ranges from 0.8 to 1.2 g / kg of body weight / day. This first stage (ketogenic) is maintained until the patient reaches the goal of reducing the target weight by 80% to be reduced, being variable in time, according to the response of each patient. After this period, it evolved to a non-ketogenic stage, initiating the hypocaloric diet (800 to 1500 Kcal), with progressive introduction of other food groups, reducing weight more slowly. The maintenance stage consists of a balanced diet, ranging from 1500 to 2000 Kcal.
Study: NCT03239834

Intervention type: DEVICE
Intervention: OncAlert
Description: A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.

Intervention type: DEVICE
Intervention: OncAlert
Description: A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.

Intervention type: DEVICE
Intervention: OncAlert
Description: A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.
Study: NCT04351217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Raga Ahir Bhairav and Bhairavi were used, played primarily on flute, without lyrics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: The instructions were recorded in both English and the local language, Kannada
Study: NCT03479086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 200mg/day 100mg b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 50mg/day
Study: NCT01671254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FishOil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FishOil
Study: NCT03563066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 \& 56.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Subcutaneous placebo injections once per month for 3 months on Days 0, 28 \& 56.
Study: NCT01671254

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FishOil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CBE75

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CBE150

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT00470366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Study: NCT02604446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual pain treatment
Description: premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: usual pain treatment
Description: premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: usual pain treatment
Description: premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
Study: NCT03061357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity tracker
Description: Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
Study: NCT00470366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02943811

Intervention type: DEVICE
Intervention: UTERINE MANIPULATOR
Description: Patients were operated laparoscopically with the aid or not of an intrauterine probe to manipulate the uterus
Study: NCT02434497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Description: Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
Study: NCT03827655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-954 Placebo
Description: TAK-954 placebo-matching intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954 Placebo
Description: TAK-954 placebo-matching intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954 Placebo
Description: TAK-954 placebo-matching intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.
Study: NCT01768637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81 mg by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg by mouth once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg by mouth once daily
Study: NCT02474563

Intervention type: DRUG
Intervention: Bortezomib
Description: Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.

Intervention type: DRUG
Intervention: Melphalan
Description: Participants receiving Melphalan 9 mg/m\^2 will be observed in this study.

Intervention type: DRUG
Intervention: Prednisone
Description: Participants receiving Prednisone 60 mg/m\^2 will be observed in this study.
Study: NCT03168620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration
Study: NCT02598024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Focused Behavioural Treatment
Description: The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
Study: NCT03238365

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Given orally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT01533480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zirgan
Description: 0.15% ganciclovir gel(Zirgan)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: genteal gel
Description: 0.3% Hypromellose gel
Study: NCT01588431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
Description: Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
Study: NCT00484458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interspinous process and dynamic stabilization (Wallis System)
Description: Interspinous stabilization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Disc Replacement
Description: Total disc
Study: NCT04498338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization combined with conventional physical therapy program
Description: Neural mobilization of sciatic nerve combined with TENs and exercise program applied 3 times/week for successive 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy program
Description: TENs and exercise program applied 3 times/week for successive 6 weeks.